MediciNova receives notice of allowance for MN-001 from Chinese Patent Office
MediciNova announced that it has received a Notice of Allowance from the Chinese Patent Office for a pending patent application which covers MN-001, or tipelukast, for the treatment of idiopathic pulmonary fibrosis, or IPF. Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than May 2035. The allowed claims cover the use of MN-001 for treating a patient diagnosed with idiopathic pulmonary fibrosis. The allowed claims also cover the inhibition of pulmonary scarring, the reduction or inhibition of elevated lung hydroxyproline levels, the reduction of elevated lung density, and the reduction of elevated total cell count in bronchoalveolar lavage fluid using MN-001. The allowed claims cover oral administration, including tablets and capsules, as well as liquid dosage forms.